http://www.acc.org/Feed?clinicalTopicID=77363932-163e-4e60-acc9-30166483412d Clinical Topic Feed: Cardiovascular Care Team en /Latest-in-Cardiology/Journal-Scans/2026/04/16/17/02/Higher-CV-Risk Patients and survivors of hematological malignancies face substantially elevated short- and long-term risk of cardiovascular disease compared with the general population – with risk varying significantly by malignancy subtype, according to a population-based cohort study published April 8 in JACC. 1776442380000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/04/15/17/20/Does-Early-Surgery Early surgical aortic valve replacement (SAVR) led to a lower incidence of operative mortality or cardiovascular-related death at 10 years in patients with very severe aortic stenosis (AS), according to an extended follow-up of the RECOVERY trial published March 25 in NEJM. 1776358260000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/04/15/17/20/Real-World-TTVR In the first year of its approval in the U.S., transcatheter tricuspid valve replacement (TTVR) in patients with severe tricuspid regurgitation (TR) was found to be safe and effective by STS/ACC TVT Registry data, showing 30-day outcomes consistent with the TRISCEND II pivotal trial... 1776278460000 Articles and Stories /Latest-in-Cardiology/Articles/2026/04/15/13/28/eagles-eye-view-15apr2026 In this week’s View, Dr. Eagle explores four recent articles that examine how we care for patients. First, Dr. Eagle looks at a new state-of-the-art review that outlines a multidisciplinary framework for cardiogenic shock survivorship. 1776259800000 Articles and Stories /Latest-in-Cardiology/Articles/2026/04/13/18/35/Transcatheter-Aortic-Valve-Implantation Transcatheter aortic valve implantation (TAVI) has become a cornerstone therapy for patients with severe aortic stenosis across a wide spectrum of clinical presentations and surgical risk. Initially reserved for patients at prohibitive or high surgical risk, TAVI is now widely adopted in populations at intermediate and low risk... 1776119820000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/04/09/17/44/balance-model The lower price for semaglutide established by the Center for Medicare and Medicaid Innovation's (CMMI's) Better Approaches to Lifestyle and Nutrition for Comprehensive Health (BALANCE) model, taking effect in January 2027, could produce savings that would offset the cost of treating an additional 550,000 to 3.6 million Medicare beneficiaries who qualify for expanded obesity-indication coverage, according to a Research Letter published April 2 in JAMA. 1775758020000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/04/08/14/08/State-of-the-Art-Review-Cardiogenic-Shock With survival rates after cardiogenic shock (CS) increasing, a JACC State-of-the-Art Review outlines a multidisciplinary, longitudinal approach to CS care aimed at "providing a clinically actionable structure for care pathways, resource planning and future research." 1775658600000 Articles and Stories /Latest-in-Cardiology/Articles/2022/01/01/01/01/ACC-Featured-Jobs Ready to explore a new professional opportunity? Browse the list below of featured jobs and take the next step in your career! 1775037480000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/25/21/27/sat-930am-championaf-acc-2026 Device-based left atrial appendage (LAA) closure was comparable to non-vitamin K antagonist oral anticoagulant (NOAC) therapy in reducing the combined rate of death from cardiovascular causes, stroke, or systemic embolism at three years in patients with atrial fibrillation (AFib) who were candidates for anticoagulation, based on findings from the CHAMPION-AF trial presented at ACC.26 and simultaneously published in NEJM. In addition, LAA closure was superior to long-term NOAC therapy for pre-specified non–procedure-related bleeding over the same time period. 1774708380000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/03/24/18/20/ACC-Scientific-Statement-Highlights-Emerging-Role-of-Gene-Editing A new ACC Scientific Statement outlines the rapidly evolving landscape of gene-editing therapies and their growing relevance to cardiovascular disease, offering clinicians an overview of both the promise and the challenges of this transformative technology. 1774536660000 Articles and Stories